DSC127 is a novel angiotensin analog, which has been shown to improve epithelialisation, granulation, vascularisation, and accelerate wound healing in a variety of normal and diabetic animal models.
The contract is a part of the HHS radiological and nuclear threats preparedness strategy, and could be extended for a total of five years and up to a total of $14m.
Derma Sciences had recently reported positive results from Phase II study evaluating DSC127 in diabetic foot ulcer healing.
The results showed that 54% of wounds healed completely in 12 weeks, compared to only 33% of wounds in patients receiving placebo and best standard of care in the intent to treat populations.
